Sofosbuvir add-on to ribavirin for chronic hepatitis E in a cirrhotic liver transplant recipient: a case report.
Fiche du document
24 mai 2019
- doi: 10.1186/s12876-019-0995-z
- issn: 1471-230X
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1186/s12876-019-0995-z
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/31126238
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1471-230X
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_10FD0B1931C26
info:eu-repo/semantics/openAccess , CC BY 4.0 , https://creativecommons.org/licenses/by/4.0/
Sujets proches
Non-A, non-B hepatitis, Enterically-transmitted Enterically-transmitted non-A, non-B hepatitis Waterborne hepatitis Epidemic non-A, non-B hepatitis Hepatitis, Non-A, non-BCiter ce document
M. Fraga et al., « Sofosbuvir add-on to ribavirin for chronic hepatitis E in a cirrhotic liver transplant recipient: a case report. », Serveur académique Lausannois, ID : 10.1186/s12876-019-0995-z
Métriques
Partage / Export
Résumé
Chronic hepatitis E represents an emerging challenge in organ transplantation, as there are currently no established treatment options for patients who fail to clear hepatitis E virus (HEV) following reduction of immunosuppressive therapy and/or treatment with ribavirin. Sofosbuvir has shown antiviral activity against HEV in vitro but clinical utility in vivo is unknown. We describe a 57-year-old liver transplant recipient with decompensated graft cirrhosis due to chronic hepatitis E. Reduction of immunosuppressive treatment as well ribavirin alone for 4 months did not result in viral clearance. Add-on of sofosbuvir for 6 months was associated with HEV RNA becoming undetectable in plasma. However, sustained viral clearance could not be achieved. Sofosbuvir may have some antiviral activity against HEV when added to ribavirin. However, this did not suffice to yield sustained viral clearance. Our well-characterized observation emphasizes the need for new treatment options to cure chronic hepatitis E in the setting of organ transplantation.